ASP Isotopes PET Lab Revenue Grows Over 50% in First Half of Year, Isotope Enrichment Facilities Advance Toward Commercial Production
ASP Isotopes Inc. recently released a letter to shareholders outlining operational progress across its business segments ahead of the company's second-quarter 2026 financial results announcement. The company stated that its PET lab segment achieved organic revenue growth of more than 50% in the first half of 2026 compared to the same period in 2025. Based on current expectations, the segment's full-year 2026 revenue is projected to be approximately $14 million, up from $6 million in 2025. PET-related operations are typically closely associated with radiopharmaceutical preparation, molecular imaging, and nuclear medicine diagnostic applications. On the isotope front, ASP Isotopes stated that its silicon-28 and ytterbium-176 enrichment facilities have entered the final stage before commercial production, with first deliveries expected in the second half of 2026...
2026-08-05
